We utilized the availability of small molecule inhibitors of CHK1 (UCN-01 and AZD 7762) and RRM1 and RRM2 (gemcitabine), to test the efficacy of these compounds on human TNBC cells as well as the M6 cell line derived from the C3(1)/Tag mammary tumors. Here, CHEK1 is linked to breast cancer.